PFE Pfizer Inc: Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Pfizer Inc. (PFE) profitability is subject to intense patent battles and pressure from generics. The forward net income trend clearly demonstrates a shift in market expectations, where the parameter value equals -3.10. The behemoth is currently restructuring its R&D toward oncology, leveraging global distribution capabilities and the acquisition of promising biotech startups to solidify its monopoly status.

Pfizer Inc. (PFE) is currently transforming its R&D strategy, shifting its focus toward oncology drugs following the decline in revenues from COVID-19 products. This metric measures the average expected growth rate of earnings per share, directly impacting the calculation of a fair P/E ratio. The narrowing range of forecasts signals that the market has reached a consensus regarding future cash flows. By analyzing changes in the consensus estimate for net profit growth, an investor can identify the moment institutional players revalue the business.